elosulfase alfa (vimizim) Report issue

Biologics Recombinant protein Orphan Drug FDA Approved FDA First in Class Fast Track FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW
  • Now
Elosulfase alfa, sold under the brand name Vimizim, is a medication used for the treatment of Morquio syndrome which is caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase. Elosulfase alfa is a synthetic version of this enzyme.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$875.1100 - $1156.6400
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

bmn-100 | bmn 110 | bmn-110 | ec 3.1.6.4 | elosulfase alfa | galactosamine (n-acetyl)-6-sulfate sulfatase, human | galactose-6-sulfate sulfatase, human | galnac6s protein, human | galns protein, human | morquio syndrome protein, human | mucopolysaccharidosis type iva protein, human | n-acetylgalactosamine-6-sulfatase | n-acetylgalactosamine-6-sulfatase, human | rhgalns | vimizim | vimzim

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (2)


 

Mucopolysaccharidoses

Mucopolysaccharidosis IV

Experimental Indications - Clinical Trial Phases 1-4 (2)


 

Mucopolysaccharidoses (Phase 3)

Mucopolysaccharidosis IV ()

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue